2017
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cellular And Molecular Gastroenterology And Hepatology 2017, 3: 163-173. PMID: 28275683, PMCID: PMC5331831, DOI: 10.1016/j.jcmgh.2017.01.006.Peer-Reviewed Original ResearchColorectal cancerHigh-risk patient cohortEarly detectionEffective prognostic indicatorTreatment of patientsTumor immune therapyNew therapeutic regimensColorectal tumor biologyCurative resectionIntrahepatic recurrenceRecurrent diseaseSystemic therapyTreatment toxicityLiver metastasesImmune therapyTreatment regimensPrognostic indicatorTherapeutic regimensCancer carePatient cohortMetastatic spreadTreatment responseHigh riskPrognostic studiesPatients
2012
Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer
Hessman C, Bubbers E, Billingsley K, Herzig D, Wong M. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. The American Journal Of Surgery 2012, 203: 649-653. PMID: 22405917, PMCID: PMC4285581, DOI: 10.1016/j.amjsurg.2012.01.003.Peer-Reviewed Original ResearchConceptsAldehyde dehydrogenase 1Cancer stem cellsClinical outcomesLoss of expressionCSC marker aldehyde dehydrogenase 1Advanced stage colorectal cancerMarker expressionMetastatic CRC samplesAmerican Joint CommitteeLate-stage diseaseColorectal cancer progressionEffective therapeutic targetNonmetastatic CRCMetastatic diseaseEarly CRCALDH1 expressionColorectal cancerCancer stageCRC tumorsCRC samplesTumors variesDisease prognosisNonmetastatic tumorsTherapeutic targetJoint Committee
2009
T1555 Outcomes from Liver Resection for Metastatic Colorectal Cancer in the Age of FOLFOX Chemotherapy
Sally M, Orloff S, Sheppard B, Khan S, Billingsley K. T1555 Outcomes from Liver Resection for Metastatic Colorectal Cancer in the Age of FOLFOX Chemotherapy. Gastroenterology 2009, 136: a-910. DOI: 10.1016/s0016-5085(09)64208-6.Peer-Reviewed Original Research
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimens
2006
Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study
Whitehead R, McCoy S, Wollner I, Wong L, Harker W, Hoff P, Gold P, Billingsley K, Blanke C. Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study. Journal Of Clinical Oncology 2006, 24: 3598-3598. DOI: 10.1200/jco.2006.24.18_suppl.3598.Peer-Reviewed Original ResearchPrior chemotherapy regimensAdvanced colorectal cancerPhase II trialColorectal cancerEligible patientsChemotherapy regimensII trialPerformance statusSouthwest Oncology Group studyCommon grade 2Prior chemotherapy regimenZubrod performance statusMetastatic colorectal cancerMonths overall survivalColorectal cancer patientsSerum magnesium levelsSignificant anti-tumor activityKaplan-Meier estimatesAdditional active agentsAnti-tumor activityHistone deacetylase inhibitorsMurine model systemBaseline labsMeasurable diseasePrior regimensCurrent Status of Colorectal Cancer Therapy
Strother J, Billingsley K, Hung A, Blanke C. Current Status of Colorectal Cancer Therapy. 2006, 273-285. DOI: 10.1007/978-1-59745-172-7_23.Peer-Reviewed Original Research